Верхнее меню

Prospects of Pharmacological Intervention in New SARS-COV-2 Coronavirus and COVID-19 Caused by it



M.B. Ivanov
E.B. Shustov
V.L. Reinyuk
m.b.ivanov@toxicology.ru
shustov-msk@mail.ru
vladton@mail.ru
Director of the Institute of Toxicology of Federal Medical Biological Agency of Russia, corresponding member of the Russian Academy of Natural Sciences, Doctor of Medicine
Chief Researcher, the Institute of Toxicology of Federal Medical Biological Agency of Russia, professor, the Department of Pharmacology and Clinical Pharmacology, St. Petersburg Chemical and Pharmaceutical University of the Ministry of Health of the Russian Federation, member of the Russian Academy of Natural Sciences, Winner of the State Prize of the Russian Federation in Science and Technology, Doctor of Medicine, professor
deputy director for scientific research, the Institute of Toxicology of Federal Medical Biological Agency of Russia, Doctor of Medicine
St. Petersburg
St. Petersburg
St. Petersburg

Keywords:

  • COVID-19
  • SARS-CoV-2
  • hypoxemia
  • coronavirus
  • acute respiratory distress syndrome
  • pathogenetic therapy
  • multiple organ failure
  • We analyze the elements of pathogenesis of the most life-threatening specific manifestations of the clinical picture of the disease in question. We show that Covid-19 is a special type of viral pneumonia whose severe form is manifested as a multi-organ disease resulting from both direct viral tissue damage and systemic disorders, namely, intravascular thrombosis and microcirculation disorders, anemia, hypoxemia and hypoxia of mixed genesis, endotoxicosis, kidney and liver failure. The pathological process is triggered by the cytokine "storm" and immune damage as well as developing an acute respiratory distress syndrome. Despite the fact that both clinical and biomedical studies of drugs that can be potentially effective for the infection caused by the new coronavirus are actively conducted in many countries, an effective Protocol for treating such patients has not yet been developed neither nationally nor internationally. We list the main pathogenetic drugs promising for patients suffering from the new coronavirus infection to reduce the severity of the disease and reduce the risk of severe complications.